NASDAQ:GRFS

GRIFOLS S A/S Stock Forecast, Price & News

$16.25

+0.53 (+3.37 %)

(As of 09/23/2020 12:00 AM ET)

Add

Compare

Today's Range

$15.71

Now: $16.25▼

$16.29

50-Day Range

$15.40

MA: $16.84▼

$19.08

52-Week Range

$13.40

Now: $16.25▼

$25.73

Volume1.42 million shs

Average Volume1.16 million shs

Market Capitalization$11.17 billion

P/E Ratio18.06

Dividend Yield1.08%

Beta0.69

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for GRIFOLS S A/S.

2.0 Community Rank

Outperform Votes
GRIFOLS S A/S has received 313 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
GRIFOLS S A/S has received 455 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
GRIFOLS S A/S has received 59.24% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote “Outperform” if you believe GRFS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days.

1.7 Dividend Strength

Dividend Yield
GRIFOLS S A/S has a dividend yield of 1.08%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
GRIFOLS S A/S does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of GRIFOLS S A/S is 14.53%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, GRIFOLS S A/S will have a dividend payout ratio of 11.33% next year. This indicates that GRIFOLS S A/S will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GRIFOLS S A/S insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 17.98% of the stock of GRIFOLS S A/S is held by institutions.

2.5 Earnings and Valuation

Earnings Growth
Earnings for GRIFOLS S A/S are expected to grow by 16.28% in the coming year, from $1.29 to $1.50 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GRIFOLS S A/S is 18.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 18.18.
Price to Earnings Ratio vs. Sector
The P/E ratio of GRIFOLS S A/S is 18.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.55.
Price to Earnings Growth Ratio
GRIFOLS S A/S has a PEG Ratio of 1.04. PEG Ratios around 1 indicate that a company is correctly valued.
Price to Book Value per Share Ratio
GRIFOLS S A/S has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.23 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:GRFS

Previous Symbol

CUSIPN/A

CIK1438569

Webwww.grifols.com

Phone34-93-571-0000

Debt

Debt-to-Equity Ratio0.97

Current Ratio2.86

Quick Ratio1.18

Price-To-Earnings

Trailing P/E Ratio18.06

Forward P/E Ratio12.60

P/E Growth1.04

Sales & Book Value

Annual Sales$5.71 billion

Price / Sales1.96

Cash Flow$1.63 per share

Price / Cash Flow9.95

Book Value$11.15 per share

Price / Book1.46

Profitability

EPS (Most Recent Fiscal Year)$1.17

Net Income$700.16 million

Net Margins10.40%

Return on Equity10.83%

Return on Assets4.68%

Miscellaneous

Employees22,244

Outstanding Shares687,550,000

Market Cap$11.17 billion

Next Earnings Date11/3/2020 (Estimated)

OptionableOptionable

$16.25

+0.53 (+3.37 %)

(As of 09/23/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions

How has GRIFOLS S A/S's stock been impacted by Coronavirus (COVID-19)?

GRIFOLS S A/S's stock was trading at $20.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GRFS stock has decreased by 20.2% and is now trading at $16.25.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of GRIFOLS S A/S?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for GRIFOLS S A/S.

When is GRIFOLS S A/S's next earnings date?

GRIFOLS S A/S is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for GRIFOLS S A/S.

How were GRIFOLS S A/S's earnings last quarter?

GRIFOLS S A/S (NASDAQ:GRFS) issued its earnings results on Thursday, July, 30th. The biotechnology company reported $0.35 EPS for the quarter, missing the Zacks' consensus estimate of $0.37 by $0.02. The biotechnology company earned $1.52 billion during the quarter, compared to analyst estimates of $1.46 billion. GRIFOLS S A/S had a return on equity of 10.83% and a net margin of 10.40%.
View GRIFOLS S A/S's earnings history.

How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S?

GRIFOLS S A/S declared a semi-annual dividend on Thursday, October 31st. Shareholders of record on Tuesday, December 3rd will be given a dividend of $0.169 per share on Wednesday, December 11th. This represents a yield of 1.3%. The ex-dividend date is Monday, December 2nd. This is an increase from GRIFOLS S A/S's previous semi-annual dividend of $0.15.
View GRIFOLS S A/S's dividend history.

When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work?

GRIFOLS S A/S shares split on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were payable to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

Are investors shorting GRIFOLS S A/S?

GRIFOLS S A/S saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 2,180,000 shares, a decline of 11.4% from the August 15th total of 2,460,000 shares. Based on an average trading volume of 1,310,000 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.9% of the shares of the stock are sold short.
View GRIFOLS S A/S's Short Interest.

Who are some of GRIFOLS S A/S's key competitors?

Some companies that are related to GRIFOLS S A/S include Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Beigene (BGNE), Alexion Pharmaceuticals (ALXN), Genmab A/S (GMAB), Shiseido (SSDOY), UCB (UCBJF), Genmab A/S (GNMSF), Merck KGaA (MKGAF), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN) and Catalent (CTLT).
View all competitors.

What other stocks do shareholders of GRIFOLS S A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Abbott Laboratories (ABT), Alibaba Group (BABA), Johnson & Johnson (JNJ), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR).

Who are GRIFOLS S A/S's key executives?

GRIFOLS S A/S's management team includes the following people:

Mr. Raimon Grifols Roura, Co-CEO & Exec. Director (Age 55)
Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 63)
Mr. Víctor Grífols Deu, Co-CEO & Exec. Director (Age 42)
Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 61)
Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs

What is GRIFOLS S A/S's stock symbol?

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

Who are GRIFOLS S A/S's major shareholders?

GRIFOLS S A/S's stock is owned by a number of institutional and retail investors. Top institutional investors include AKO Capital LLP (1.79%), FIL Ltd (1.72%), TPG Group Holdings SBS Advisors Inc. (0.76%), Black Creek Investment Management Inc. (0.48%), First Trust Advisors LP (0.45%) and Axiom International Investors LLC DE (0.32%).

Which institutional investors are selling GRIFOLS S A/S stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including AKO Capital LLP, Bank of America Corp DE, FIL Ltd, Marshall Wace LLP, Pelham Capital Ltd., CIBC Private Wealth Group LLC, Amia Capital LLP, and GABELLI & Co INVESTMENT ADVISERS INC..

Which institutional investors are buying GRIFOLS S A/S stock?

GRFS stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., First Trust Advisors LP, TPG Group Holdings SBS Advisors Inc., Sei Investments Co., UBS Group AG, Goldman Sachs Group Inc., Black Creek Investment Management Inc., and Kornitzer Capital Management Inc. KS.

How do I buy shares of GRIFOLS S A/S?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GRIFOLS S A/S's stock price today?

One share of GRFS stock can currently be purchased for approximately $16.25.

How big of a company is GRIFOLS S A/S?

GRIFOLS S A/S has a market capitalization of $11.17 billion and generates $5.71 billion in revenue each year. The biotechnology company earns $700.16 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 22,244 workers across the globe.

What is GRIFOLS S A/S's official website?

The official website for GRIFOLS S A/S is www.grifols.com.

How can I contact GRIFOLS S A/S?

GRIFOLS S A/S's mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-0000 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings